阅读说明：本技术 人血浆线粒体融合蛋白2在作为诊断非酒精性脂肪性肝病的分子标志物中的应用 (Application of human plasma mitochondrion fusion protein 2 as molecular marker for diagnosing non-alcoholic fatty liver disease ) 是由 南月敏 杜静华 王荣琦 张玉果 赵素贤 苑喜微 李冬冬 于 2019-10-11 设计创作，主要内容包括：本发明提供了人血浆线粒体融合蛋白2在作为诊断非酒精性脂肪性肝病的分子标志物中的应用,属于肝病诊断技术领域,所述人血浆线粒体融合蛋白2可作为诊断非酒精性脂肪性肝病的分子标志物,非酒精性脂肪性肝病患者的人血浆线粒体融合蛋白2水平显著降低,当人血浆中人血浆线粒体融合蛋白2的含量小于12.49ng/ml时,表明人发生了非酒精性脂肪性肝病。(The invention provides an application of human plasma mitochondrial fusion protein 2 as a molecular marker for diagnosing non-alcoholic fatty liver disease, belonging to the technical field of liver disease diagnosis, wherein the human plasma mitochondrial fusion protein 2 can be used as a molecular marker for diagnosing non-alcoholic fatty liver disease, the level of the human plasma mitochondrial fusion protein 2 of a non-alcoholic fatty liver disease patient is obviously reduced, and when the content of the human plasma mitochondrial fusion protein 2 in human plasma is less than 12.49ng/ml, the human plasma mitochondrial fusion protein 2 indicates that the non-alcoholic fatty liver disease occurs.)

1. Application of human plasma mitochondrion fusion protein 2 in diagnosis of non-alcoholic fatty liver disease.

2. The use according to claim 1, wherein the amino acid sequence of the human plasma mitochondrial fusion protein 2 is as shown in SEQ ID No. 1.

3. Use of the MFN2 gene encoding the human plasma mitochondrial fusion protein 2 of claim 1 as a molecular marker for diagnosing non-alcoholic fatty liver disease.

4. The use according to claim 3, wherein the nucleotide sequence of the MFN2 gene is represented by SEQ ID No. 2.

Technical Field

The invention belongs to the technical field of liver disease diagnosis, and particularly relates to application of human plasma mitochondrion fusion protein 2 as a molecular marker for diagnosing non-alcoholic fatty liver disease.

Background

With the improvement of living standard of people and the change of dietary structure and life style, the incidence of non-alcoholic fatty liver disease (NAFLD) is on the trend of rising year by year, and the NAFLD becomes the first major chronic liver disease and the primary reason of abnormal liver enzyme for health physical examination in China; the disease spectrum includes nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, NAFLD-related cirrhosis and hepatocellular carcinoma. NAFLD not only causes disability and death of liver diseases, but also is closely related to high incidence of metabolic syndrome, type 2 diabetes, colorectal tumor and the like, and seriously harms the life health of people. The discovery and application of reliable molecular markers is key to the early discovery of NAFLD, the timely adoption of effective measures, and the prevention of disease progression.

At present, molecular markers for accurately diagnosing the occurrence and the development of NAFLD are lacking.

Disclosure of Invention

In view of the above, the present invention aims to provide an application of human plasma mitochondrial fusion protein 2 as a molecular marker for diagnosing non-alcoholic fatty liver disease.

In order to achieve the above purpose, the invention provides the following technical scheme:

the invention provides an application of human plasma mitochondrion fusion protein 2 as a molecular marker for diagnosing non-alcoholic fatty liver disease.

Preferably, the amino acid sequence of the human plasma mitochondrion fusion protein 2 is shown in SEQ ID No. 1.

The invention also provides application of the MFN2 gene of the human plasma mitochondrion fusion protein 2 in the technical scheme as a molecular marker for diagnosing the non-alcoholic fatty liver disease.

Preferably, the nucleotide sequence of the MFN2 gene is shown as SEQ ID No. 2.

The invention provides an application of human plasma mitochondrial fusion protein 2 in a molecular marker for diagnosing non-alcoholic fatty liver disease, wherein the human plasma mitochondrial fusion protein 2 can be used as the molecular marker for diagnosing non-alcoholic fatty liver disease, the human plasma mitochondrial fusion protein 2 of a non-alcoholic fatty liver disease patient is remarkably reduced, and when the content of the human plasma mitochondrial fusion protein 2 in human plasma is less than 12.49ng/ml, the human plasma mitochondrial fusion protein 2 indicates that the human has non-alcoholic fatty liver disease.

Drawings

FIG. 1 is a pathological liver map of healthy control and NAFLD mice;

figure 2 is immunohistochemical staining of healthy controls with NAFLD mouse liver pathology MFN 2;

figure 3 is the levels of MFN2 protein expression in healthy controls versus NAFLD mice;

figure 4 is healthy control versus NAFLD mouse MFN2mRNA expression levels;

figure 5 is the levels of MFN2 protein expression in healthy controls versus NAFLD patients;

figure 6 is a comparative analysis of the expression levels of MFN2 for different liver enzyme levels in patients with NAFLD;

FIG. 7 is a ROC curve for human MFN2 protein.

Detailed Description

The invention provides an application of human plasma mitochondrion fusion protein 2 as a molecular marker for diagnosing non-alcoholic fatty liver disease. In the invention, the human plasma mitochondrion fusion protein 2 is abbreviated as Mitofusin 2, MFN 2.

In the invention, the amino acid sequence of the human plasma mitochondrion fusion protein 2 is shown in SEQ ID No.1, and is specifically shown as follows:

M S L L F S R C N S I V T V K K N K R H M A E V N A S P L K H F V T A K K K I N G I F E Q L G A Y I Q E S A T F L E D T Y R N A E L D P V T T E E QV L D V K G Y L S K V R G I S E V L A R R H M K V AF F G R T S N G K S T V IN A M L W D K V L P S G I G H T T N C F L R V E G T D G H E A F L L T E G S EE K R S A K T V N Q L A H A L H Q D K Q L H A G S L V S V M W P N S K C P L LK D D L V L M D S P G I D V T T E L D S W I D K F C L D A D V F V L V A N S ES T L M Q T E K H F F H K V S E R L S R P N I F I L N N R W D A S A S E P E YM E E V R R Q H M E R C T S F L V D E L G V V D R S Q A G D R I F F V S AK EV L N A R I Q K A Q G M P E G G G A L A E G F Q V R M F E F Q N F E R R F E EC I S Q S A V K T K F E Q H T V R A K Q I A E A V R L I M D S L H M A A R E QQ V Y C E E M R E E R Q D R L K F I D K Q L E L L A Q D Y K L R I K Q I T E EV E R Q V S T A M A E E I R R L S V L V D D Y Q M D F H P S P V V L K V Y K NE L H R H I E E G L G R N M S D R C S T A I T N S L Q T M Q Q D M I D G L K PL L P V S V R S Q I D M L V P R Q C F S L N Y D L N C D K L C A D F Q E D I EF H F S L G W T M L V N R F L G P K N S R R A L M G Y N D Q V Q R P I P L T PA N P S M P P L P Q G S L T Q E E F M V S M V T G L A S L T S R T S M G I L VV G G V V W K A V G W R L IA L S F G L Y G L L Y V Y E R L T W T T K A K E RAF K R Q F V E H A S E K L Q L V I S Y T G S N C S H Q V Q Q E L S G T F A HL C Q Q V D V T R E N L E Q E I A A M N K K I E V L D S L Q S K A K L L R N KA G W L D S E L N M F T H Q Y L Q P S R。

in the present invention, human plasma mitochondrial fusion protein 2 of non-alcoholic fatty liver disease patients was significantly reduced compared to healthy persons. When the content of human plasma mitochondrion fusion protein 2 in human plasma is less than 12.49ng/ml, the human has non-alcoholic fatty liver disease.

The invention also provides application of the MFN2 gene of the human plasma mitochondrion fusion protein 2 in the technical scheme as a molecular marker for diagnosing the non-alcoholic fatty liver disease.

In the invention, the nucleotide sequence of the MFN2 gene is shown as SEQ ID No.2, and is specifically shown as follows:

atgatgcagtgggagtccgagcctctgcgtcgtccgcttgggacgcgccggcggaggagtggcgcgcgg aggagtggcgcgctgagacgccgctcgaagcgccgagtcgcggggcagcagaggcgtaagg agtaggcggg gcgagccggctgggctcagggtccaccagctcacccgggtcgaggggcaatctgaggcgactggtgacgcgctt atccacttccctcctcccgcctccccctggggtggcgctcgctggtgacgtagtgagtgtgatggccgccgcgagg ccgggaaggtgaagcgcaatgtccctgctcttctctcgatgcaactctatcgtcacagtcaagaaaaataagagaca catggctgaggtgaatgcatccccacttaagcactttgtcactgccaagaagaagatcaatggcatttttgagcagctgggggcctacatccaggagagcgccaccttccttgaagacacgtacaggaatgcagaactggaccccgttaccacagaagaacaggttctggacgtcaaaggttacctatccaaagtgagaggcatcagtgaggtgctggctcggaggcacatgaaagtggctttttttggccggacgagcaatgggaagagcaccgtgatcaatgccatgctctgggacaaagttct gccctctgggattggccacaccaccaattgcttcctgcgggtagagggcacagatggccatgaggcctttctcctta ccgagggctcagaggaaaagaggagtgccaagactgtgaaccagctggcccatgccctccaccaggacaagca gctccatgccggcagcctagtgagtgtgatgtggcccaactctaagtgcccacttctgaaggatgacctcgttttgat ggacagccctggtattgatgtcaccacagagctggacagctggattgacaagttttgtctggatgctgatgtgtttgtg ctggtggccaactcagagtccaccctgatgcagacggaaaagcacttcttccacaaggtgagtgagcgtctctccc ggccaaacatcttcatcctgaacaaccgctgggatgcatctgcctcagagcccgagtacatggaggaggtgcggc ggcagcacatggagcgttgtaccagcttcctggtggatgagctgggcgtggtggatcgatcccaggccggggacc gcatcttctttgtgtctgctaaggaggtgctcaacgccaggattcagaaagcccagggcatgcctgaaggaggggg cgctctcgcagaaggctttcaagtgaggatgtttgagtttcagaattttgagaggagatttgaggagtgcatctcccag tctgcagtgaagaccaagtttgagcagcacacggtccgggccaagcagattgcagaggcggttcgactcatcatgg actccctgcacatggcggctcgggagcagcaggtttactgcgaggaaatgcgtgaagagcggcaagaccgactg aaatttattgacaaacagctggagctcttggctcaagactataagctgcgaattaagcagattacggaggaagtgga gaggcaggtgtcgactgcaatggccgaggaga。

the technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.